Skip to main content
Bild Studie POInT
NiDerLander - stock.adobe.com

POInT Study

Please note that participation in the POInT study is no longer possible!

Type 1 diabetes is an autoimmune disease. This means that the immune system, which primarily serves to defend the body against germs, attacks and destroys the insulin-producing cells (beta cells) in the islets of Langerhans in the pancreas. The aim of the Primary Oral Insulin Trial (POInT study) is to prevent the destruction of the insulin-producing cells of the pancreas in children with an increased risk of type 1 diabetes and therefore prevent the development of type 1 diabetes. The presence of beta-cell autoantibodies is an indication of the inflammation and destruction of the insulin-producing cells in the pancreas.

The POInT study aims to prevent these autoantibodies from developing by training the immune system so that this mistaken immune reaction does not occur. This is done with insulin powder, which is given daily together with a meal. The body’s own insulin is often the first target of the mistaken immune reaction, which leads to type 1 diabetes. Through exposure via the mucous membranes of the mouth and the digestive tract, the aim of the insulin powder is to train the immune system to tolerate the body’s own insulin, thereby preventing the destructive immune reaction. Unlike insulin that is injected, the insulin powder does not serve to lower the blood glucose level.

Type 1 diabetes is an autoimmune disease. This means that the immune system, which primarily serves to defend the body against germs, attacks and destroys the insulin-producing cells (beta cells) in the islets of Langerhans in the pancreas. The aim of the Primary Oral Insulin Trial (POInT study) is to prevent the destruction of the insulin-producing cells of the pancreas in children with an increased risk of type 1 diabetes and therefore prevent the development of type 1 diabetes. The presence of beta-cell autoantibodies is an indication of the inflammation and destruction of the insulin-producing cells in the pancreas.

The POInT study aims to prevent these autoantibodies from developing by training the immune system so that this mistaken immune reaction does not occur. This is done with insulin powder, which is given daily together with a meal. The body’s own insulin is often the first target of the mistaken immune reaction, which leads to type 1 diabetes. Through exposure via the mucous membranes of the mouth and the digestive tract, the aim of the insulin powder is to train the immune system to tolerate the body’s own insulin, thereby preventing the destructive immune reaction. Unlike insulin that is injected, the insulin powder does not serve to lower the blood glucose level.

Contact

Dr. Elisabeth Huber

Study Coordinator POInT Study

Heidemannstraße 1, 80939 München